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out the reception area and front desk informing patients their time
is valuable to us.
Recent results have demonstrated an increased satisfaction re-
garding the patient wait times and their perception of why they are
waiting. Continued monitoring of the Patient Satisfaction surveys
on a monthly basis with a weekly review of Comment Cards
provide direction for additional improvements.
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APHERESIS PATIENT SATISFACTION SURVEY: AN ONGOING QUALITY
IMPROVEMENT PROCESS
Sorensen, S.H., Adornetto, D.L., Stary, S., Samaniego, C., Rhodes, B.
M D Anderson Cancer Center, Houston, TX
Patient Satisfaction Surveys (PSS) measure the quality of care
delivered. The Apheresis PSS was a joint survey distributed to
outpatient Blood and Marrow Transplant (BMT) patients and
those in Apheresis. Staff felt the survey had a narrow focus as it
measured the patient’s experience at M D Anderson for that day
only. Additionally, there was no mechanism in place to track the
number of surveys distributed and returned.
Apheresis staff revised the survey to obtain information relevant
to the Apheresis unit. Surveys were distributed monthly, results
trended and discussed in monthly staff meetings. Results were
graphed and displayed on a “story board” using the institutional
quality improvement process of “Plan, Do, Check, Act.” This
allowed for an on-going process of identifying and resolving prob-
lems.
Scores remained high for all categories through out the year,
which gave the staff a good indication of how they were doing. The
lowest score noted was for waiting times after arriving to the
Apheresis unit. It was determined these scores were the lowest for
those patients undergoing Lumbar Punctures (LP). The plan for
distribution was revised and each patient undergoing a LP was
given a PSS to complete. Education was done and the scores were
tracked and trended to identify a change based on the education
provided. Surveys were given to all other patients quarterly. Scores
were also tracked, trended and actions taken based on the results.
All scores remained high and the wait time scores improved for the
LP group.
PSS are now distributed quarterly to all patients and the results
tracked, trended and reported to the staff and the BMT Quality
Improvement Committee.
The next step is validation of the PSS. A resident nurse re-
searcher is assisting the staff in this process. The plan is to reformat
the survey to assure each item only asks one question and to
identify the areas that are important to the patient. The survey will
again be distributed monthly to determine its validity, track and
trend the results, and begin action plans as indicated.
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DEVELOPING NURSING STANDARDS OF PRACTICE FOR BLOOD AND
MARROW (BMT) PATIENTS THROUGH A SHARED GOVERNANCE COUN-
CIL STRUCTURE IN PREPARATION FOR THE FOUNDATION FOR THE
ACCREDITATION OF CELLULAR THERAPIES (FACT) INSPECTION
Causton, C.A., Neumann, J.L., Jacob, R., Tischhauser, T., Weaver, V.
MD Anderson Cancer Center, Houston, TX
The inpatient, unit-based self governance clinical practice coun-
cil was very actively involved in the preparation for the Foundation
for the Accreditation of Cellular Therapies (FACT) inspection at
our large NCI designated cancer center by developing and format-
ting nursing Standards of Practice (SOP). These SOP’s were in
compliance with FACT standards that all relevant nursing proce-
dures have written policies. The clinical practice council met bi-
monthly to develop the standards. Each topic was assigned to a
different member who researched and developed the SOP having
done a literature search with the assistance of the research council
to maintain that our practice was evidence based. The draft was
presented to our council members and discussed until a completed
version was developed. The completed SOP was then formatted
according to FACT standards. Upon completion, it was reviewed
by a committee consisting of the BMT Clinical Coordinator,
Medical Director, Center Administrative Director, Nurse Man-
ager and Assistant Nurse Managers and the BMT Compliance
Ofﬁcer for ﬁnal approval. Once approved, the educational council
introduced the SOP’s to the nursing staff. All the nursing staff were
then required to review and sign off on each SOP. This included all
the units that care for BMT patients throughout the institution (ie.
Intensive care Unit, Protective Environment, Pediatrics-inpatient
unit and outpatient clinic, Outpatient BMT Clinic and Pheresis
Unit). The development and implementation of these standards
was the result of a strong collaborative effort that included other
unit based self-governance councils–the education, communication
and research councils in addition to other areas within the insti-
tution such as the Pediatric Department, the Outpatient Clinic,
Pheresis Unit and the Protective Environment. Our goal was to
ensure the highest quality of care for our BMT patients and
continuity of that care across the entire BMT program.
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SUSPECTED CATHETER RELATED BLOOD STREAM INFECTION (CRBSI)
IN HEMATOLOGY STEM CELL TRANSPLANT PATIENTS: TRACKING
RATES AND OUTCOMES
Haller, S.M., Bevans, M., Curnow, E.S., Gutierrez, D. National In-
stitutes of Health, Bethesda, MD
Central venous catheters (CVC) are a necessity for patients
undergoing treatment for hematological diseases and stem cell
transplant, but place patients at an increased risk for infection. The
incidence of CRBSI varies with clinical factors such as catheter
type and patient’s underlying disease and acuity (CDC, 2002). Due
to a perceived increase in CRBSI, patients undergoing peripheral
blood stem cell transplant or immunosuppressive therapy were
followed for suspected CRBSI over a period of approximately 4
months (March, 2002–July 2002) to determine the prevalence of
CRBSI, the treatments implemented, and outcomes. Adults (N 
105) participating in a clinical trial were admitted to an inpatient
unit with various hematology and oncology diagnoses. Thirty
(29%) were identiﬁed with new fever and/or blood cultures for
suspected CRBSI with no other sources evident. These patients
were evaluated by the vascular access device team and hospital
epidemiology service. Eleven patients (37%) had temporary CVCs
and nineteen (63%) had tunneled CVCs. Patients with tunneled
catheters were more likely to present with signs and symptoms
consistent with CRBSI greater than ﬁfteen days post catheter
insertion as compared to temporary lines (n  14 vs. n  2).
Patients with temporary catheters were more likely to present with
signs and symptoms consistent with CRBSI less than 15 days post
catheter insertion (n  5 vs. n  9). Of the 30 suspected CRBSI,
63% (n  19) had negative CVC blood cultures. Sixteen of these
patients had IV antibiotic therapy initiated upon admission. Ten
(33%) CVCs were removed due to suspected CRBSI; four of them
subsequently had negative blood cultures. This project drew atten-
tion to the important issue of CVC assessment and care within the
interdisciplinary team caring for this population. Policy, proce-
dures, and educational materials were updated to reﬂect current
standards of practice. The CVC standard of practice and patient
teaching tool were revised, and included a new dressing change
technique and schedule. A new tracking method via the occurrence
reporting system was implemented with an organization based
system for continuous quality monitoring for patients with CVCs.
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NON-MYELOABLATIVE STEM CELL TRANSPLANT PATIENT EDUCATION
Johns, A.A., Davis, P.H., Lassiter, M.E., Loftis, J.F., Rowe, K.L. Duke
University Medical Center, Durham, NC
Non-myeloablative stem cell transplantation is being studied in a
number of transplant centers. The reduced intensity of the condi-
tioning regimen offers the opportunity for transplantation to pa-
tients who are older or have comorbid conditions that previously
would have precluded stem cell transplantation (Neiderweiser et al
2003).While this approach holds promise it is still investigational
(Devine et al 2003).
The less intense chemotherapy and/or radiation reduce the in-
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cidence of acute toxic effects of the conditioning regimen (Maris et
al 2001) but require a greater patient and family participation in the
direct care. Many transplant centers plan to have all or part of the
care provided in the outpatient setting and need the support of
families and friends as caregivers. Much of the printed education
materials available to transplant patients is directed to ablative
transplants and can be misleading to patients and families. The
Allogeneic Patient Handbook at Duke Adult Stem Cell Transplant
(ASCT) Program contains patient instructions for high dose abla-
tive transplants.
Duke University Medical Center performed 36 non-myeloabla-
tive transplants in ﬁscal year 2003. Only 22% of these patients were
admitted to the hospital. The majority of the patients received all
of their care in the Adult Outpatient Clinic and at home with
assistance from home care services and family caregivers. A new set
of teaching guidelines, materials and methods need to be developed
in order to meet the changing education needs of transplant pa-
tients.
Prior to developing new materials and processes, the non-my-
eloablative transplant patients were surveyed by the ASCT pro-
gram nursing staff to determine how the current handbooks met
the educational needs and what opportunities did we have to
improve the content and the process. Patient satisfaction surveys
were also used to determine patient satisfaction with the educa-
tional process.
The Non-myeloablative Patient Handbook was written and re-
viewed by the Adult BMT Clinical Staff and approved by the Duke
Oncology Patient Education Committee.
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IMPLEMENTING BROVIAC CATHETER USE IN PHOTOPHERESIS FOR
CHRONIC GVHD IN PEDIATRIC HSCT PATIENTS
Fisher, V.L., Jekutis, B., Smucker, T. Rainbow Babies and Children’s
Hospital/Ireland Cancer Center, Cleveland, OH
The use of photophersis in the treatment of chronic GVHD has
been well documented in the adult HSCT patient population.
However, the use of photophersis in the pediatric HSCT patient
remains a formidable challenge, due to central access issues. May
institutions require pheresis catheter placement for photopheresis.
We report a series of 142 successful photopheresis sessions in ﬁve
pediatric patients utilizing a double lumen broviac catheter. All of
the patients had malignacies (2 ALL and 3 AML) The patients
ranged in age from 8-15 years and with weights of 20.1 kg to 58 kg
respectively. The number of photopheresis sessions for the patients
ranged from 8 to 52. The ECP procedure was performed using the
UVAR XTS photopheresis system (Therakos, West Chester, Pa)
as previously described. The mean treatment time for each pho-
topheresis procedure was 3.5 hours. The ﬂow rate during each
photophersis procedure averaged 10-12 ml/minute. Only one of
the ﬁve patients experienced hypovolemia as an adverse event,
successfully treated with ﬂuid replacement. There were no other
adverse events related to photopheresis. The use of tPA was re-
quired occasionally prior to the start of the procedure. We con-
clude that the use of a broviac catheter is a safe and practical
alternative to apheresis catheters for management of chronic
GVHD in pediatric HSCT patients.
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HEALTH-RELATED QUALITY OF LIFE AND SYMPTOM DISTRESS IN
PATIENTS PRIOR TO ALLOGENEIC STEM CELL TRANSPLANT
Bevans, M.1, Marden, S.1, Mayberry, H.1, Cusack, G.1, Soeken, K.2,
Kline Leidy, N.3 1. National Institutes of Health, Clinical Center,
Nursing and Patient Care Services, Bethesda, MD; 2. University of
Maryland, Baltimore, MD; 3. MEDTAP International, Bethesda, MD
Objective: This study examined health-related quality of life
(HRQL) and symptom distress (SD) in patients preparing to un-
dergo allogeneic stem-cell transplant (A-SCT) for the treatment of
hematological diseases. Methods: Prospective survey of patients
enrolled in an A-SCT clinical trial. HRQL was measured by the
physical (PCS) and mental (MCS) health scores of the Short
Form-36 (norm  50) and the Functional Assessment of Cancer
Therapy-General (FACT-G; range 0-100). SD was measured by
the Symptom Distress Scale (SDS; range 13-65). Patients com-
pleted the questionnaires in English or Spanish via a touch-screen
computer during the trial baseline period. Scores were compared
to published references for the 1998 general United States (US)
population (GP) and a cancer population (CP) using one sample
t-tests. Scores were also grouped by gender and compared to the
male/female GP using one sample t-tests. A p-value 0.05 was
considered signiﬁcant. Findings: Patients (N  76) were mostly
male (67%), ranging in age from 18-71 years (M  40; SD  14),
and either Caucasian (46%) or Hispanic (30%). Most (97%) had
ECOG 1. Baseline results demonstrated mean PCS and MCS
scores of pre-A-SCT patients were signiﬁcantly lower than the GP
(norm 50 vs. 43, p 0.001 and 47, p 0.015, respectively). The
mean PCS score for male patients was signiﬁcantly lower than male
GP (norm  51 vs. 42; p  0.001); mean MCS score did not differ
(norm  51 vs. 49; p  0.20). For female patients, the mean MCS
score was signiﬁcantly lower than female GP (norm  50 vs. 43;
p  .017); mean PCS score did not differ (norm 49 vs. 44; p 
0.05). FACT-G total score was signiﬁcantly lower than patients
with Hodgkin’s Disease (59 vs. 66; p  0.001). SDS scores (76%)
indicated low SD (25); 24% indicated moderate distress (range
25-32). Conclusion: Patients with hematological diseases, ECOG
1, prior to A-SCT have poorer HRQL compared to the US GP
and a cancer population, with relatively low levels of SD. Men
report more concerns related to physical health compared to men
in the GP. Women report more concerns related to mental health
compared to women in the GP.
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CONTINUOUS PLATELET DRIP: A UNIQUE APPROACH IN THE TREAT-
MENT OF SEVERE/REFRACTORY THROMBOCYTOPENIA IN THE PEDI-
ATRIC STEM CELL TRANSPLANT POPULATION
Talbert, G.1,2, Zbylut, C.1, Chelf, K.1, Frey, M.A.1,2, Martin, P.2,
Kurtzberg, J.2 1. The Duke University Children’s Hospital, Durham,
NC; 2. The Pediatric Stem Cell Transplant Program at Duke Univer-
sity, Durham, NC
Thrombocytopenia is an expected complication of marrow abla-
tive therapy. Platelets are the last hematopoietic cell to ablate and
the last to recover after conditioning for tranplant. Bleeding re-
mains a signiﬁcant cause of morbidity and morality in the im-
munosuppressed patients. Patients undergoing stem cell transplan-
tation are at greater risk due to the prolonged duration and severe
nature of the aplastic period. Therefore, long term supportive care
via platelet transfusion is a common and expected therapy in this
patient population. As a result of therapy, many patients become
refractory to platelet transfusions. These patients may require
more intensive measures that include frequent platelet transfusions
or continuous platelet drips to prevent complications from bleed-
ing. To further complicate matters, many patients undergoing
transplantation are often ﬂuid sensitive and at times ﬂuid re-
stricted. The added volume of multiple platelet transfusions can
pose additional risk to an already fragile patient. The use of
continuous platelet drips has proven to be an effective way to treat
severe/refractory thrombocytopenia and minimize the additional
ﬂuid volume. The Duke Pediatric Stem Cell Transplant Unit
utilizes continuous platelet drips for select patients. Patients re-
ceiving this therapy must meet speciﬁc criteria including throm-
Table. Patient Demographics
Age Sex Diagnosis HSCT Source GVHD
10 F ALL CR3 MUD-PB (6/6) Extensive
13 M ALL CR2 MUD-BM (6/6) Extensive
15 F AML CR2 MRD-PB (5/6) Extensive
15 M AML CR1 MRD-BM (5/6) Extensive
8 M AML CR3 UCB (4/6) Extensive
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